Press release
Polymyositis Market Size in the 7MM was ~USD 114 million in 2023, estimated DelveInsight
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.Discover Key Insights into the Polymyositis Market with DelveInsight's In-Depth Report @ Polymyositis Market Size [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Polymyositis Market Report
* In December 2024:- Cabaletta Bio- Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
* In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
* Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
* Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
* The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
* The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
* Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous , and others.
Stay ahead in the Polymyositis Therapeutics Market with DelveInsight's Strategic Report @ Polymyositis Market Outlook [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polymyositis Epidemiology Segmentation in the 7MM
* Total Polymyositis Diagnosed Prevalent Cases
* Polymyositis Gender-specific Diagnosed Prevalent Cases
* Polymyositis Age-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polymyositis Emerging Drugs
* SAPHNELO (Anifrolumab): AstraZeneca
SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.
* Dazukibart (PF-06823859): Pfizer
The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.
Polymyositis Market Outlook
Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient's response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.
Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Polymyositis Market Report
* Coverage- 7MM
* Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
* Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
* Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
* Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers
Unlock Strategic Insights with DelveInsight's Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1 Key Insights
2 Report Introduction
3 Polymyositis Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary
7 Disease Background and Overview
8 Epidemiology and Patient Population of Polymyositis
9 Patient Journey
10 Emerging Therapies
11 Polymyositis: Seven Major Market Analysis
12 KOL Views
13 SWOT Analysis
14 Unmet needs
15 Market Access and Reimbursement
16 Appendix
17 Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
18 Bibliography
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyositis-market-size-in-the-7mm-was-usd-114-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polymyositis Market Size in the 7MM was ~USD 114 million in 2023, estimated DelveInsight here
News-ID: 3769492 • Views: …
More Releases from ABNewswire

Factory Automation Market: Valued at $224.1 Million in 2024, Projected to Reach …
Factory Automation Market Research Report Information By Type (Fixed Automation, Programmable Automation, Flexible Automation, Integrated Automation), By Technology (SCADA, Programmable Automation Controller (PAC), PLC, Distributed Control System (DCS), Human Machine Interface (HMI)), By End User (Manufacturing, Automotive, Packaging & processing, Energy & Power, Semiconductor & Electronics & Others), And By Region (North America, Europe, Asia-Pacific & Rest Of The World) - Forecast Till 2032
The Factory Automation Market was valued at…
![Autonomous Trucks Market Size, Share & Trends [2035]](https://cdn.open-pr.com/2/1/217961713_g.jpg)
Autonomous Trucks Market Size, Share & Trends [2035]
Autonomous Trucks Market by LoA (L1, L2/ L3, L4 & L5), Vehicle Type, Propulsion (Diesel, Electric, Hybrid), ADAS Features, Vehicle Class, Application, Sensor Type and Region - Global Forecast to 2035
The global autonomous trucks market [https://www.marketsandmarkets.com/Market-Reports/semi-autonomous-bus-market-87328844.html?utm_source=abnewswire&utm_medium=referral&utm_campaign=semi-autonomous-bus-market] size is projected to grow from USD 40.7 billion in 2024 to USD 179.9 billion by 2035, at a CAGR of 14.4%. The Autonomous trucks market is witnessing robust growth driven by increasing demand…

Poultry Vaccines Market Sales Statistics, Growth Outlook and Developments To 203 …
Global Poultry Vaccines Market Research Information and Growth Outlook 2025 By Diseases (Infectious Bronchitis, Marek's Disease), By Technology (Toxoid, Recombinant, Inactivated, Live Attenuated Vaccines), By Dosage Form (Duct, Liquid, Freeze Dried Vaccines) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Industry Forecast Till 2032
The poultry vaccines market is on the verge of substantial expansion, fuelled by breakthroughs in artificial intelligence, machine learning, and robotics. A…

IBN Technologies Encourages U.S. Taxpayers to Take Action for Bigger 2024 Tax Re …
As the 2025 tax season approaches, taxpayers must take a strategic approach to maximize refunds and stay compliant amid evolving tax laws. Understanding eligible deductions and credits can help individuals keep more of their earnings, while businesses must navigate complex regulations to avoid overpaying. Optimizing tax filings, staying informed on policy changes, and seeking expert guidance can reduce liabilities, prevent penalties, and secure financial stability.
MIAMI, Florida, February 17, 2025 -…
More Releases for Polymyositis
Polymyositis Market Size, Share, Region & Country Revenue Analysis & Forecast Ti …
Reports and Data has recently published a new report on the Global Polymyositis Market that offers key insights into the current and emerging trends, key companies and market size and market share on a global and regional level. Despite weak development in Western economies as a whole, M&A (mergers and acquisitions) activity in the healthcare sector has increased dramatically. Not only is there a strong growth in pharmaceutical companies,…
Idiopathic Inflammatory Myopathy Treatment Market Worth $930.6 Million by 2026; …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…
Polymyositis Treatment Market Technology, Recent Trends, Demand, Future Growth, …
The Global Polymyositis Treatment Market 2022, which focuses on the Polymyositis Treatment market, evaluates the key components using a top to bottom methodology and allows the client to survey the drawn-out based interest while also forecasting explicit executions. This research conducts an in-depth investigation, clarifies item scope, and expands on industry experiences and perspectives until 2028. The Global Polymyositis Treatment market is a crucial source of information for important and…
Polymyositis Treatment Market Is Projected To Witness Vigorous Expansion By 2026 …
Data Bridge Market Research has recently added a concise research on the Polymyositis Treatment Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological…
Idiopathic Inflammatory Myopathy Treatment Market 2020: Global Share, Industry O …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights(TM) published this information in an upcoming report, titled, "Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…
Idiopathic Inflammatory Myopathy Treatment Market 2020 Global Growth Factor, Siz …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights(TM) published this information in an upcoming report, titled, "Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…